Steffan Ho, MD;PhD

San Diego, California, United States
Steffan N. Ho is currently Vice President and Head of Translational Oncology in the Global Product Development organization at Pfizer. As a board-certified pathologist and principal research investigator with over 20 years of clinical, academic and industry experience, Dr. Ho brings together an understanding of clinical diagnostics, human cancer, tumor biology, precision medicine, technology platforms, and drug development. He has contributed to precision oncology efforts supporting the approval of a number of targeted therapies and companion diagnostic tests benefiting patients with solid tumor and hematologic malignancies. He currently provides leadership in Translational Oncology across a broad clinical pipeline of oncology and immuno-oncology medicines in various phases of drug and associated companion diagnostic test development.
Dr. Ho completed his undergraduate degree at Carleton College and received his MD and PhD degrees from the Mayo Clinic where he completed doctoral studies Immunology. He pursued postgraduate medical training in anatomic pathology and postdoctoral research in molecular immunology in the Department of Pathology and the Howard Hughes Medical Institute at the Stanford University Medical Center and holds a medical license with board certification in Anatomic Pathology. He has previously held positions on the faculty in the School of Medicine at the University of California-San Diego in the Departments of Pathology and Cellular and Molecular Medicine, and at Biogen in Discovery and Translational Oncology.
Speaking In
1:45 PM - 2:45 PM (PDT)
Tuesday, June 14
Given a less than 8% likelihood for a New Drug Approval from first in man clinical trials, drug…